Chimeric Therapeutics Limited researches, develops, and commercializes cell therapies for cancer in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.31|
|52 Week High||AU$0.24|
|52 Week Low||AU$0.44|
|1 Month Change||-4.61%|
|3 Month Change||5.09%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||5.09%|
Recent News & Updates
|CHM||AU Biotechs||AU Market|
Return vs Industry: Insufficient data to determine how CHM performed against the Australian Biotechs industry.
Return vs Market: Insufficient data to determine how CHM performed against the Australian Market.
Stable Share Price: CHM is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CHM's weekly volatility (7%) has been stable over the past year.
About the Company
Chimeric Therapeutics Limited researches, develops, and commercializes cell therapies for cancer in Australia. The company develops CLTX CAR T cell therapy that is in Phase I clinical study for Glioblastoma; and CDH17 CAR T, which is in preclinical study for neuroendocrine tumours, as well as colorectal, pancreatic, and gastric cancer. It has a strategic partnership with OncoBay Clinical for the development program of CLTX CAR T. The company was incorporated in 2020 and is based in Carlton, Australia.
Chimeric Therapeutics Fundamentals Summary
|CHM fundamental statistics|
Is CHM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CHM income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.045|
|Net Profit Margin||0.00%|
How did CHM perform over the long term?See historical performance and comparison
Is Chimeric Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CHM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CHM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CHM is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: CHM is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CHM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CHM is good value based on its PB Ratio (4.1x) compared to the AU Biotechs industry average (4.9x).
How is Chimeric Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CHM's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if CHM's earnings are forecast to grow faster than the Australian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CHM's revenue is forecast to grow faster than the Australian market.
High Growth Revenue: CHM is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CHM's Return on Equity is forecast to be high in 3 years time
How has Chimeric Therapeutics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CHM is currently unprofitable.
Growing Profit Margin: CHM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if CHM's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare CHM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: CHM has a negative Return on Equity (-60.14%), as it is currently unprofitable.
How is Chimeric Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CHM's short term assets (A$22.7M) exceed its short term liabilities (A$7.4M).
Long Term Liabilities: CHM's short term assets (A$22.7M) exceed its long term liabilities (A$4.0M).
Debt to Equity History and Analysis
Debt Level: CHM is debt free.
Reducing Debt: CHM had no debt 5 years ago.
Debt Coverage: CHM has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CHM has no debt, therefore coverage of interest payments is not a concern.
What is Chimeric Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CHM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CHM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CHM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CHM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CHM's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Jennifer Chow has been a Director of Chimeric Therapeutics Limited since August 30, 2021. She serves as the Managing Director & Chief Executive Officer of Chimeric Therapeutics Limited since August 30,...
Experienced Management: CHM's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: CHM's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CHM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: CHM only recently listed within the past 12 months.
Chimeric Therapeutics Limited's employee growth, exchange listings and data sources
- Name: Chimeric Therapeutics Limited
- Ticker: CHM
- Exchange: ASX
- Founded: 2020
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$98.366m
- Shares outstanding: 333.44m
- Website: https://www.chimerictherapeutics.com
- Chimeric Therapeutics Limited
- 62 Lygon Street
- Level 3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 07:02|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.